Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma.

cdkn2a loss low grade glioma malignant transformation pilocytic astrocytoma pten loss

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
23 May 2019
Historique:
entrez: 30 7 2019
pubmed: 30 7 2019
medline: 30 7 2019
Statut: epublish

Résumé

This case of a radiation-naive patient with pilocytic astrocytoma highlights how deletions of CDKN2A (cyclin-dependent kinase Inhibitor 2A) and PTEN (phosphatase and tensin homolog) portended a poor clinical outcome. Pilocytic astrocytomas are grade 1 tumors usually occurring in children and young adults with KIAA1549-BRAF fusion defining the majority of pilocytic astrocytomas. The presence of CDKN2A and PTEN loss may be associated with aggressive biology in pilocytic astrocytoma and further studies should include comprehensive genomics in a larger series of adult pilocytic astrocytoma to evaluate this previously unreported finding. Providers need to be aware of this possibility given the potential for poor outcomes.

Identifiants

pubmed: 31355086
doi: 10.7759/cureus.4726
pmc: PMC6649926
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e4726

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cancer Res. 2008 Nov 1;68(21):8673-7
pubmed: 18974108
Am J Surg Pathol. 2010 Feb;34(2):147-60
pubmed: 20061938
Acta Neuropathol. 2011 Mar;121(3):407-20
pubmed: 21113787
Nat Genet. 2013 Jun;45(6):602-12
pubmed: 23583981
Nat Genet. 2013 Aug;45(8):927-32
pubmed: 23817572
J Clin Oncol. 2015 Mar 20;33(9):1015-22
pubmed: 25667294
J Child Neurol. 1994 Jul;9(3):301-10
pubmed: 7930411

Auteurs

Daniel N Cagney (DN)

Radiation Oncology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Michael B Miller (MB)

Pathology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Adrian Dubuc (A)

Pathology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Ivana Delalle (I)

Pathology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Azra H Ligon (AH)

Pathology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Ugonma Chukwueke (U)

Neuro-Oncology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Ossama Al-Mefty (O)

Neurosurgery, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Ayal Aizer (A)

Radiation Oncology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Keith Ligon (K)

Pathology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Patrick Wen (P)

Neuro-Oncology, Dana-Farber / Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA.

Classifications MeSH